Introduction
The relatively low number of investigators in the field of human T cell leukemia/lymphoma viruses types I and II (HTLV-I and HTLV-II), is due, in part, to the higher degree of emergency and funding in the field of human immunodeficiency virus (HIV). This should not obscure the important role that the study of HTLV has played in virology in particular and in biomedical sciences in general. The discovery of HTLV-I in 1980 demonstrated that retroviruses existed in humans. The methods developed to culture T-lymphocytes and isolate HTLV-I were instrumental in the isolation and expansion of the human immunodeficiency virus (HIV), the cause of AIDS, the major pandemic of our time. HTLV-I is associated with adult T cell leukemia/lymphoma (ATL) and with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Understanding the biology of HTLV-I not only helped understand these diseases, but is a model for similar disorders, where an association with this or other viruses has not been demonstrated at present. For instance, HAM/TSP is a model for demyelinating disorders such as multiple sclerosis. The field of HTLV has also spawned or helped development in many areas. It has led to the discovery of interleukin-2 receptor and of the cytokines interleukin (IL)-9 and IL-15. The discovery of the viral transactivator Tax, a protein that increases viral expression and regulates the expression of cellular genes as well as that of Rex, another viral protein that shuttles back and forth from the nucleus and regulates the export of unspliced or singly-spliced mRNA from the nucleus, has opened new areas of research on basic mechanisms of transcriptional and post-transcriptional regulation. These concepts were instrumental in elucidating the key function of proteins with similar function in HIV, such as Tat and Rev. HTLV-I has been used to immortalize T-lymphocytes and this has helped to determine the nature of cytokines produced by T-lymphocytes, for instance chemokines produced by CD8 + T-lymphocytes, that have paved the way to the discovery of HIV coreceptors. The first Tax transgenic mouse model, where neurofibromas develop, helped pinpoint the importance of the constitutive activation of the nuclear factor (NF)-B pathway as one of the major signal transduction mechanisms of at least some tumoral conditions. The list is not complete and only serves to underscore the major role of HTLV-I research in the biosciences. For this reason we are indebted to Genoveva (Veffa) Franchini, Steve Jacobson and Kuan-Teh Jeang for having organized such an excellent meeting on 'HTLV-Molecular Biology and Pathogenesis', that analyzed the current and most important issues in HTLV research, in terms of molecular mechanisms and pathogenesis. This meeting was sponsored by the National Cancer Institute (NCI), the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Allergy and Infectious Diseases (NIAID). What follows is a summary of the different issues that were presented and discussed during the meeting.
Gene expression and regulation
The multi-faceted actions of Tax HTLV-1 Tax has the following molecular effects: (1) Activation of transcription through interaction of Tax with CBP/p300 (activation of CREB-, NF-B-and SRF-responsive genes): this leads to increased expression of HTLV-I, interleukin (IL)-2, IL-2-receptor (IL-2R) ␣, IL-6, tumor necrosis factor (TNF)-␣. (2) Repression of transcription through interaction of Tax with CBP/p300: this may lead to decreased expression of cellular genes, such as p18, NF-1, Lck, Bax, DNA polymerase ␤. (3) Dysregulation by Tax of cell cycle regulatory proteins, such as p16, p15, p53, c-Myb. This leads to disruption of normal regulation of cell cycle and increased proliferation. (4) Increase of genetic instability through repression of p53-dependent transcription and through interaction with hMAD1 (human mitotic checkpoint MAD1 protein, mitotic arrest deficient phenotype) and topoisomerase I. This leads to accumulation of mutations and to an increase in chromosomal anomalies, favoring the development of ATL. Interaction of Tax with hMAD1 leads to decreased expression of DNA polymerase ␤. Interaction of Tax with topoisomerase I leads to decreased activity of that enzyme. The latter effect is mediated by an inhibition by Tax of relaxation of supercoiled DNA, inhibition of binding of topoisomerase I to DNA and decreased covalent binding of topoisomerase I to chromosomal DNA. The site of action of Tax on topoisomerase I is different from that of camptothecin.
Mechanisms for Tax-induced stimulation of HTLV-I expression
Tax strongly stimulates HTLV-I expression. This is mediated by the binding of Tax to: (1) HTLV-I CRE (cAMP-responsive element) in the promoter region of the virus; (2) to the cellular transcription factor CREB (CRE-binding protein), that binds to the CRE octanucleotide sequence within the viral CRE; (3) and to CBP (CREB binding protein). CBP is a coactivator, that helps in the activation of many transcription factors. CBP is also an important protein in hematopoiesis. A knockout in one of the Leukemia two alleles leads to deficient T and B cell development in mice and to a 40% incidence of leukemia within 1 year of murine life. The CBP gene is fused to the MLL gene in the t(11;16)(q23;p13) translocation, associated with therapyrelated acute leukemia. Both HTLV-I Tax and phosphorylated CREB (pCREB) bind to a domain of CBP, called KIX. Tax binding to the KIX domain of CBP is strongly dependent on both pCREB and viral CRE DNA. Tax thus helps create a high affinity binding to CREB, CBP and the HTLV-I CRE promoter region. Efficient formation of this stable transcription factor complex requires binding to the viral CRE DNA. This leads to a strong recruitment of the HTLV-I promoter, resulting in HTLV-I expression driven by the strong transactivating function of Tax on the HTLV-I genome.
Tax also binds to a carboxy terminal region of CBP, called CR2. There is also a binding of p53 to the CR2 region of CBP. Tax and p53 binding to CR2 are mutually exclusive. Possibly Tax displaces p53 from CBP, making p53 less active and leading to accumulation of mutations. Tax binding to KIX of CBP is a promoter-dependent interaction, while Tax binding to CR2 of CBP is promoter-independent.
Molecular mechanisms for Tax-induced activation of NF-B
Tax is known to play an important role in HTLV-I-induced T cell proliferation and immortalization. This is mediated at least in part, by the activation of the NF-B pathway, resulting in constitutive expression of the transcription factor NF-B. NF-B stimulation, is due to phosphorylation of its inhibitor, IB. Phosphorylation of IB leads to ubiquitination and proteasomal degradation, allowing for nuclear translocation and activation of NF-B. Tax induces phosphorylation of IB, by inducing IB kinase (IKK). Tax binds to the amino terminus of MAPK/ERK kinase kinase 1 (MEKK-1) and associates with the catalytic IKK-␤ subunit and the regulatory IKK-␥ subunit (the latter also known as NF-B essential modulator or NEMO). Tax, IKK-␤ and IKK-␥ may be in the same complex. Association of IKK-␥ with MEKK-1 leads to phosphorylation and increased kinase activity of IKK-␤, leading to IB phosphorylation and NF-B activation. Activation of IKK-␥ is not only essential for NF-B activation by Tax, but also for NF-B activation by T cell mitogens. While the carboxy terminus leucine zipper motif of IKK-␥ is essential for NF-B activation by mitogens, it is another domain located in the amino terminus, that is required and sufficient for binding of Tax to IKK-␥.
Tax induces IL-2 independence and resistance to apoptosis through the NF-B pathway
Stable expression of HTLV-I Tax in the IL-2-dependent CTLL-2 murine T cell line led to IL-2-independent growth. This IL-2-independent growth is mediated by the NF-B, but not by the CRE pathway. Tax expression in the CTLL-2 cell line is also associated with resistance to apoptosis after IL-2 deprivation. This resistance to apoptosis is due to induction of expression of Bcl-xl. In a T cell line, Tax transactivates the promoter of bcl-xl and this effect is mediated through the NF-B pathway acting on a NF-B-like element in the bcl-xl promoter.
Cellular protein targets of Tax
Cellular protein targets of Tax include (among others) hMAD1, IKK-␥, Tax-binding protein (TXBP) 151, TXBP121, TXBP31 (GPS2).
TXBP151, a nuclear protein that can stimulate transcription, not only has a Tax-binding activity, but also interacts with the apoptosis inhibitor A20 zinc finger protein and has a suppressive effect on NF-B. Transactivating activity of TXBP151 is stimulated by insulin and by A20 and is inhibited by Tax. It is possible that transcriptional repression by Tax may be mediated by TXBP151. Both Tax and TXBP151 activate the AP-1 transcription factor in an additive way. Distinct mitogenactivated protein kinase kinase kinases (MAP3K) are involved in NF-B and AP-1 activation: the former is activated by NF-B-inducing kinase (NIK), the latter by MEKK 1-4 and mixedlineage kinase (MLK).
TXBP121 is a centrosomal protein. Overexpression of TXBP121 leads to splitting and hyperamplification of centrosomes, changes also seen in HTLV-I-transformed cells. Part of Tax co-localizes with TXBP121 in centrosomes. This suggests that also at the centrosomal level, can Tax influence cell cycle progression.
Defective mitotic checkpoint due to Tax
Interaction of Tax with hMAD1 results in inactivation of the latter protein and in a defective mitotic checkpoint in HTLV-I-infected cells. This is strongly suggested by experiments, where treatment of HTLV-I-transformed cell lines with nocodazole (a tubulin depolymerizer, thus a mitotic spindle inhibitor) results in a reduction of mitotic index as compared to control Jurkat and HeLa cells, but also in resistance to apoptosis both in IL-2-dependent as in IL-2-independent HTLV-I-infected cell lines. A defective mitotic checkpoint is compatible with the numeric chromosomal anomalies and multinucleated giant cells seen in ATL.
One of the Tax paradoxes: increased apoptosis but also escape from it, with mutations
Tax expression is associated with a reduction of cellular DNA repair: nucleotide excision repair (NER) activity is reduced following UV irradiation. Tax expression also induces apoptotic cell death, especially when there is exposure to DNA damaging agents (UV, chemotherapy), but not when Tax works alone. Tax-mediated apoptosis is independent of p53 expression. Tax-mediated apoptosis can be blocked by caspase inhibitors and by members of the bcl-2 family. At the same time, Tax-expressing cells show increased DNA replication, more rapid cell cycle progression, even when they are exposed to DNA damaging agents. This may be the mechanism for Tax-mediated malignant transformation, in that Taxexpressing cells accumulate mutations as a result of DNA damage. The damage can lead to increased apoptosis, but at least part of the cells may progress in the cell cycle, despite DNA damage, resulting in transmission of mutations to progeny cells and increasing the risk of malignant transformation.
It was stressed during the meeting that DNA damage usually only leads to apoptosis if the cell cycle checkpoints are functioning. This is a problem in HTLV-I-infected cells, which do not arrest in G1. Tax appears to increase the expression of PCNA (proliferating cell nuclear antigen) and may interfere with the G 1 /S checkpoint. PCNA is an essential regulator of DNA replication and repair. Outside the context of HTLV-I, DNA damage induces p53 which induces p21/waf1. p21/waf1 interacts with PCNA, resulting in a G 1 block of DNA replication, allowing time for DNA repair. But in the context of Tax, there is an increased PCNA expression, part of which binds to p21/waf1 and part of which remains free. Free PCNA will stimulate DNA replication, even if no DNA repair has occurred. In addition, Tax blocks p53 function, which has the consequence that not too much p21/waf1 is around to deal with DNA damage, which increases the proportion of free PCNA even more. Incidently, the G 2 /M checkpoint is also problematic in HTLV-I-infected cells because of functional hMAD1 inactivation due to Tax.
Tax-induced p53 inactivation through the NF-B pathway
Usually, the function of p53 is impaired in HTLV-I-infected cells, although there is generally no mutation in the p53 gene. It has been demonstrated that HTLV-I Tax inactivates p53 and this is correlated with hyperphosphorylation at serine-15 and serine-392 of p53. The ability of Tax to activate NF-B is essential for the inactivation of p53 function. Overexpression of p300 does not rescue p53 activity in the presence of Tax, demonstrating that Tax-induced p53 inactivation is not due to the coactivator titrating out p53. On the other hand, IB␣ restores p53 activity. There is still disagreement as to whether the CREB pathway also plays a role in Tax-induced p53 inactivation. In HUT102 cells and in cord blood cells infected with HTLV-I derived from the C88 cell line, Tax-mediated p53 inactivation is independent of binding to CREB or of LTR activation. On the other hand, the CREB pathway has been reported to be necessary for p53 inactivation in Jurkat cells and in adherent cell lines.
p53 inactivation by HTLV-II Tax
p53 is also inactive in HTLV-II-infected cell lines. This is also correlated with hyperphosphorylation of p53 at serines-15 and -392. HTLV-IIA Tax is less active in p53 inactivation than HTLV-IIB Tax and HTLV-I Tax. HTLV-IIA and HTLV-IIB have equal activity on HTLV-I LTR. HTLV-IIA is slightly deficient in NF-B activation in T cells.
Failure to arrest in G 1 following DNA damage, not p53-induced apoptosis, is deficient in a model of Taxexpressing cells
HTLV-I-infected cells display an increased frequency of chromosomal aberrations. It is believed that this is due at least in part to cellular genomic instability in response to Tax expression. In a model of de novo Tax-producing cells without previous selection for positive growth characteristics, it was observed that upon UV-induced DNA damage, DNA repair was deficient, but that there was normal stabilization of p53 and adequate stimulation of apoptosis. What was not normal in those Tax-producing cells, was that G 1 arrest did not occur following UV damage and that cells went on to proceed from G 1 -to S-phase, leading to accumulation of cells with a 4n genome. This serves to underscore that in that system of Taxexpressing cells, not the p53 control, but one of the cell cycle Leukemia checkpoints is deficient. Most probably this is due to interaction of Tax with the human mitotic checkpoint protein hMAD1.
Tax immunolocalization studies
Immune localization studies have demonstrated the presence of Tax in the nucleus of a Jurkat-derived T cell line, in the nucleus and cytoplasm of a fibroblastic cell line derived from the tumor of a Tax transgenic mouse and mostly in the cytoplasm of T cells cultured from the peripheral blood of patients with ATL.
HTLV-I infection and IRF-4
Interferon regulatory factor (IRF-4) is a member of the family of nine known IRF transcription proteins. IRF-4 has oncogenic potential and its gene is implicated in the t(6;14)(p25;q32) chromosomal translocation in multiple myeloma, where it is known under the name of MUM-1 (Multiple Myeloma-1). IRF-4 is constitutively expressed in HTLV-I-infected cell lines. HTLV-I Tax induces Jurkat cells to express IRF-4 and activates the promoter of the IRF-4 gene. Using a yeast two-hybrid screen, an interaction was demonstrated between IRF-4 and FK506-binding protein 52 (FKBP52), a member of the immunophilin family that has peptidyl-prolyl isomerase (PPIase) activity. FKBP52 inhibits DNA binding and transcription stimulation by IRF-4, probably by a PPIase-induced modification (cis-trans prolyl isomerization) of IRF-4.
Interaction of Tax with the c-myb and B-myb genes
Tax also trans-represses the promoter of the c-myb and the Bmyb genes, through the NF-B pathway, and independently of its interaction with CBP or p300. Low levels of c-Myb are found in HTLV-I-infected cell lines. This is a strange phenomenon, as one would expect that HTLV-I, in stimulating the proliferation of infected T cells, would use oncogenes like cmyb and/or B-myb, that are known to play a role in respectively G 1 /S transition and S phase progression. It is as if Tax takes over the control over the G 1 /S transition and bypasses (down-regulates) c-myb and B-myb in order to tailor the infected cell to its own need. Maybe normal or increased cmyb and B-myb expression would interfere with Tax's own action. This is not the first interesting paradox of Tax.
Cell cycle and transformation

High frequency of somatic mutations in HTLV-Iinfected individuals
Sequencing of HTLV-I RU5 sequence and flanking somatic sequences revealed multiple mutations, including somatic mutations. Mutation frequency was correlated with HTLV-I proviral copy number and was more than a thousand times higher than the frequency of mutations due to reverse transcriptase errors only. The frequency of mutations was higher in ATL patients than in HAM/TSP patients, and higher in HAM/TSP patients than in asymptomatic HTLV-I carriers. This is compatible with Tax generating genetic instability, in that it impairs cellular DNA repair mechanisms by DNA poly-merase ␤, p53, hMAD1, base excision repair and nucleotide excision repair. The high frequency of somatic mutations, following integration of the HTLV-I proviral genome, is compatible with the eventual later development of a transformed phenotype.
In vivo expansion of T cell clones in HAM/TSP
HTLV-I infection is related to in vivo expansion of certain T cell clones in HAM/TSP patients. This was demonstrated when analyzing somatic mutations at the hprt (hypoxantine-guanine phosphoribosyltransferase) gene, used as a surrogate marker of T cell proliferation, and testing whether hprt mutants are positive by DNA PCR for the tax gene. In most of the samples from HAM/TSP patients, HTLV-I-infected cells were enriched within the hprt mutant fraction. This suggests that clonal expansion occurs as a result of increased mutation and/or increased cell division.
The importance of Tax with intact NF-B transactivating ability for immortalization
When using infectious molecular clones of HTLV-I, it was observed that viruses with tax gene mutants defective in transactivation of NF-B transcription could not immortalize peripheral blood T cells. Infectious clones with tax mutants defective in CREB activation were still able to immortalize T cells, but preferentially CD8 + T cells (in contrast to immortalization of CD4 + T cells by molecular clones with a wild-type tax).
Cellular tropism of HTLV-II revisited
HTLV-II is associated with a variant hairy cell leukemia (but in this disease the provirus was not in the hairy cells, but in the non-leukemic CD8 + T cells) and with some cases of neurological disease. HTLV-II seems to be less pathogenic than HTLV-I. There is some difference between the tropism of HTLV-I and HTLV-II. HTLV-I has in vivo a preferential tropism for CD4
+ cells and shows in vitro an enhanced transcription and virus production in CD4 
Tax and the cell cycle machinery
Tax stimulates the cell cycle in G 1 -phase and promotes the passage from G 1 to S. Retinoblastoma (Rb) protein hyperphosphorylation, one of the hallmarks of G 1 to S progression, correlates with Tax expression in human T cells. Tax is associated with a stimulation of activity of cyclin D3/cyclin-dependent kinase (CDK) 4 and cyclin D3/CDK6. In Tax-transfected fibroblasts and in HTLV-I-infected T cells, Tax binds to and stimulates the activity of CDK4 and CDK6.
Gene expression in HTLV-I-infected cells
Expression studies in HTLV-I-infected T cells revealed that genes belonging to different functional categories were upregulated: receptors and adhesion molecules (IL-2R␣, ICAM-1), signal transducers (STAT5a), chemokines (I-309), DNA repair, transcription factors (for instance E2A), cell cycle molecules (cyclins, modulators, CDK inhibitors like p21/waf1, p16/INK4a and p19), metabolism (human prostaglandin transporter, hPGT, which mediates the degradation of prostaglandins, which otherwise have a negative regulatory influence on lymphocytes). STAT5 expression seems to be linked to IL-2-independent growth of HTLV-I-transformed cells.
There was also high expression of the mRNA encoding the anti-apoptotic chemokine I-309. Supernatant of ATL cell lines protect thymoma cell lines from apoptosis. Since ATL cell lines also express CCR8, the receptor of I-309, it is possible that an autocrine loop exists for that chemokine, protecting ATL cells from apoptosis.
The mystery of increased p21/waf1 expression in HTLV-I-infected cells
p21/waf1 is overexpressed in all HTLV-I cell lines examined and in samples from patients with ATL and HAM/TSP. Tax transactivates the p21/waf1 gene promoter, independently of p53. The p21/waf1 gene promoter contains two E2A transcription factor binding sites. The E2A proteins E12 and E47 are up-regulated in HTLV-I-infected T cells. p21/waf1 complexes with cyclin A/CDK2. This is associated with hypophosporylation of retinoblastoma (Rb) protein. One would expect that p21/waf1 overexpression in HTLV-I-infected cells would lead to cell cycle inhibition, but the reality is different, as we know. The following picture may be emerging from this complex situation. In stress circumstances, like UV irradiation, there is an increase of E47, which leads to an increase of p21/waf1; this is associated with a higher p21/waf1 level, predominant presence of p21/waf1 in the nucleus and p21/waf1 phosphorylation. The phosphorylation of p21/waf1 in the p21/cyclin A/CDK2 complex leads to inhibition of passage from G 1 -to S-phase of the cell cycle (cell cycle arrest). In Taxexpressing cells the complex of p21/waf1, CDK2 and cyclin A could rather lead to cell growth for the following reasons:
(1) the level of p21/waf1 is not high enough to act as a CDK inhibitor; (2) p21/waf1 is not phosphorylated; (3) part of p21/waf1 is probably present in the cytoplasm. p21/waf1 in the cytoplasm could have an anti-apoptotic effect.
MDM-p14 ARF regulatory loop is probably not responsible for p53 impairment in ATL
ATL cells do not undergo apoptosis following DNA damage induced by ionizing radiation. There is stabilization of p53 in all primary, non-cultured ATL cells studied thus far ex vivo. There is no genetic mutation of p53, but there is functional impairment of p53 function. It was investigated whether this was associated with anomalies in the MDM-p14 ARF regulatory loop (p53 can interact with MDM-2 in the cytoplasm and with p14 ARF in the nucleus). MDM-p14 ARF regulatory loop is most probably not responsible for the p53 impairment and there is no overexpression of p14 ARF in HTLV-I infected cells.
HTLV pathogenesis
Tax-reactive T cells in HAM/TSP
There is a high frequency of Tax 
High level in HAM/TSP of interferon-␥ + CD8 + T cells with a memory/effector phenotype
HAM/TSP patients have an HTLV-I proviral load that is higher than that of asymptomatic carriers. This correlates with the frequency of interferon-␥ + CD8 + T cells. At least some of those CD8 + T cells react against HTLV-I Tax, since they produce interferon-␥ when brought in contact with HLA-matched T cells prepulsed with an immunodominant HTLV-I peptide. In addition, using soluble divalent HLA-immunoglobulin fusion proteins, it was determined that 0.6-13.2% of peripheral blood CD8
+ T cells of HAM/TSP patients react against Tax(11-19) peptide. In HAM/TSP, the memory and/or effector subtypes were markedly increased in Tax-specific CD8 + cells. The CD45RA +
CD27
− effector phenotype correlated with the HTLV-I proviral load, while the CD45RA − CD27 + memory phenotype inversely correlated with it. This suggests that in HAM/TSP there is a higher proviral load, leading to continuous stimulation by HTLV-I antigens and associated with a high frequency of memory and/or effector CD8
+ cells and with a differentiation of memory into effector cells. This high level of interferon-␥ + CD8 + cells is most probably related to the inflammatory damage seen in HAM/TSP.
Efficient control by CTL of HTLV-I-infected cells in vivo
The majority of HTLV-I-infected individuals have chronically activated cytotoxic T-lymphocytes (CTL) directed against HTLV-I Tax, especially the immunodominant peptide . A high proportion of naturally infected CD4 + T-lymphocytes (10-100%) are capable of expressing Tax after a short term in vitro culture. Autologous CD8 + T cells show a very low level of Tax expression in culture, but are able to kill Tax-expressing CD4 + T cells in vitro by a perforin-dependent mechanism. There is a negative correlation in vivo between the frequency of CD4 + T cells in peripheral blood and the frequency of Tax(11-19) peptide-specific CD8
+ T-lymphocytes. This strongly suggests that virus-specific CTL are highly Leukemia efficient in controlling Tax-expressing HTLV-I-infected cells in vivo.
T cell spontaneous proliferation in HAM/TSP is due to IL-2 + IL-15 and their receptors
T cell from patients with HAM/TSP are known to be able to proliferate spontaneously. This spontaneous proliferation seen in culture in the absence of added cytokines is mediated by the spontaneous production of IL-2 and IL-15 by HTLV-Iinfected cells and by the spontaneous expression of IL-2R␣ and IL-15R␣ on the membrane of HTLV-I-infected cells. Combination of antibodies against IL-2 and IL-15 was able to block completely the spontaneous proliferation of peripheral blood mononuclear cells from HAM/TSP patients. Up-regulation of IL-15 and IL-15R␣ in HTLV-I-infected T cells is due to Tax activating the IL-15 and the IL-15R␣ gene promoters. Activation of the IL-15 gene promoter by Tax is abolished when the NF-B site is eliminated from the IL-15 gene promoter. In both early and late ATL there is still IL-15 production, but only in early ATL is there spontaneous proliferation; the latter can still be blocked in part by IL-15 antibodies. It was remarked during the conference that in vitro IL-15 preferentially stimulates the growth of CD8 + T cells and/of natural killer (NK) cells. IL-15 transgenic mice show a marked proliferation of NK cells. According to some participants to the meeting, the spontaneous T cell proliferation seen in HAM/TSP involves mainly CD8
+ T cells, that are usually not infected in vivo by HTLV-I.
Effect of HTLV-I on cells of the central nervous system
HAM/TSP is associated with increased levels of inflammatory cytokines (TNF-␣, IL-6 and IL-1) in the cerebrospinal fluid. HIV-1-based retroviral vectors with an HTLV-I tax insert are able to transduce up to 50% of cultured human macrophages and microglial cells. This was associated with an up-regulation of the inflammatory cytokines in transduced human microglial cells.
The thesis according to which HTLV-I-infected T cells cause alterations in astrocytes by the action of Tax and inflammatory molecules is supported by the following experimental observations. HTLV-I-infected T-lymphocytes induce the secretion of inflammatory cytokines such as TNF-␣, II-1␣ and IL-6 in astrocytes. They also induce increased production of matrix metalloproteinase (MMP)-9 and endogenous MMP inhibitors (TIMP-1 and TIMP-3). Astrocytes co-cultured with HTLV-Iinfected T-lymphocytes show a markedly decreased uptake of extracellular glutamate, a down-regulation of glial transporters GLAST and GLT-1 and a respectively increased and decreased expression of glutamine synthetase and glutamate dehydrogenase. This results in overproduction and extracellular accumulation of glutamate, leading to edema and possibly to subsequent neurodegenerative processes. Decreased glutamate uptake by astrocytes is mediated by HTLV-I Tax and by TNF-␣. The former probably induces the latter, as the effect of Tax can be abolished by anti-TNF-␣ antibodies.
Syncytium formation by HTLV-I
HTLV-I infects mainly by fusion of infected cells with uninfected cells (i.e. by syncytium formation). This fusion is mediated by the HTLV-I envelope on the surface of infected cells and VCAM-1, ICAM-1, ICAM-3 and the membrane permease CD98 on the target cells. Most likely integrin ␣3, that associates with the heavy chain of CD98, is involved in CD98-regulated HTLV-I specific fusion.
Animal models
In one model of Tax transgenic mice, a natural killer cell (NK) leukemia develops. In these transgenic mice, Tax expression is still ongoing, tumoral cells are IL-2-dependent and express IL-6, IL-10, interferon-␥ and high levels of NF-B and of IL-15. Upon culture in vitro of splenocytes from these Tax transgenic mice, there is down-regulation of Tax expression, but there is proliferation in the absence of mitogenic stimuli and there is resistance to apoptosis. Tax transgenic mice, that are p53 −/+ , show a more rapid formation but not an increased incidence of tumors than p53 +/+ Tax transgenic mice. At least in that model, Tax (and probably cytokines) thus seem to be important for immortalization, while p53 mutation is correlated with disease progression.
Immune competent adult rats inoculated with the HTLV-Iinfected MT-2 cells are persistently infected with HTLV-I, but only animals inoculated by the intravenous or intraperitoneal route but not by the oral route, develop anti-HTLV-I antibodies. Newborn rats infected with HTLV-I also develop into seronegative HTLV-I carriers. This demonstrates that the route of infection and the age at infection may play a role in determining whether an immune response develops. An experimental rat model was developed, where HTLV-I T-lymphoproliferative disease develops. An HTLV-I infected T cell line was developed from a rat heterozygous for the athymic nude mutation (nu/+). The original T cell line did not cause tumors when injected into syngeneic adult homozygous nu/nu rats, but a subline was developed after a while in culture that causes T cell lymphomas in nu/nu rats. This lymphoma development could be blocked by adoptive transfer of T-lymphocytes from syngeneic nu/+ rats, that had been preimmunized with the original cell line. Also, HTLV-I lymphomas with lung invasion develop in euthymic (+/+) rats, treated with monoclonal antibodies against co-stimulatory signals for T cell immune response (anti-CD80 and anti-CD86). These experiments show that both clonal progression of HTLV-I-infected cells and T cell immunity against HTLV-I play a role in the development of HTLV-I lymphomagenesis. This suggests that vaccination with HTLV-I or HTLV-I Tax may have a prophylactic anti-tumoral effect in HTLV-I carriers with low immune responses to HTLV-I or Tax.
The squirrel monkey Saimiri sciureus can be infected with HTLV-I. Squirrel monkey lymphocytes can be infected by HTLV-I. Peripheral blood lymphocytes, spleen and lymph nodes were the major reservoir for HTLV-I. Expression of tax/rex mRNA was found in spleen and lymph nodes. There was also evidence for cytotoxic T cell response against HTLV-I Tax and Env.
Accessory factors
Determinants of HTLV-I infectivity
HTLV-I is a poorly infective virus in vitro. Different assays have been developed to assay determinants of HTLV-I infectivity and replication. Infection assays include primary T cell immortalization, spreading infection assays and single round infection assays. Especially using the latter two assays, it was demonstrated that the half-life of HTLV-I cell-free virus at 37°C is 3 h; that it is preferable to collect virus-containing supernatant 6 to 8 h after infection; and that co-cultures are more efficient than cell-free virus for infectivity purposes. It was also determined that the HTLV-I envelope in itself is not responsible for the poor infectivity of HTLV-I. The high frequency of defective HTLV-I proviruses, usually seen in vivo, was also observed in vitro after cell-free infection using virus obtained after transfection of a full-length proviral clone. This may be due to the low levels of reverse transcriptase found in HTLV-I particles.
A 'new' HTLV-I gene: p9
The in vitro infectivity assays also revealed the importance of a 9-kDa HTLV-I protein (p9), encoded by the C-terminal region of the HTLV-I protease gene. The N-terminus of p9 is also the N-terminus of reverse transcriptase. Mutations in the p9 gene abolished HTLV-I infectivity, most probably due to post-entry events, since they were not associated with anomalies in virion morphology.
that selective ablation of p12 I will result in reduced infectivity of resting T cells.
HTLV-I p12 I protein binds to the ␥ c chain and to the acidic region of ␤ chain of of the IL-2R, the latter mediating signaling through the Jak/STAT and MAP kinase pathways. p12 I expression leads to increased STAT signaling through the IL-2R ␤ chain. In order for IL-2R signaling to be increased by p12 I , IL-2R ␤ and ␥ c chains, Jak3 and STAT5 are all needed. STAT-5 activation does not seem to be due to decreased proteasomal degradation under the influence of p12 I , since the rate of decay of STAT5 signal was not modified by p12
I . HTLV-I p12 I may also play a role in helping HTLV-I evade detection by the immune system. Indeed it has been observed that p12 I binds to major histocompatiblity complex (MHC) class I heavy chain molecules in a pre-Golgi compartment, leading to their proteasomal degradation, before the MHC molecules are able to interact with ␤ 2 -microglobulin. This could lead to decreased expression of MHC class I heavy chain on the cell surface, interfering with antigen presentation by infected cells.
Thus II to mitochondria is due to a previously undescribed 10-amino acid signal sequence. HTLV-I p13 II binds mainly to the inner membrane of the mitochondria, leading to changes in mitochondrial morphology (eg swelling) and to loss of mitochondrial inner membrane potential. But in contrast to cells not infected by HTLV-I, where such a mitochondrial membrane potential change leads to release of cytochrome C and to apoptosis, the latter two phenomena are not observed in HeLa-Tat cells that have been transfected with the p13 II gene.
HTLV-I p13
II interacts with at least two cellular proteins: C44, a member of the nucleoside monophosphate kinase family, likely to be a mitochondrial protein; and C254, which is identical to actin binding protein 280. This was established by using the yeast two-hybrid system.
The p30 II /Tof protein localizes to the nucleolus and is homologous to transcription factors Oct-1, Oct-2, Pit-1 and POU-M1. Previously it has been shown that p30 II contains a positively charged domain that targets to the nucleus and that is interchangeable with the nuclear localization signal (NLS) of HTLV-I Rex. 
More evidence for the expression of pX accessory genes in vivo
Although a function has been demonstrated for the HTLV-I ORF I and II in vivo (needed for infection in rabbits), there is still scepticism among some HTLV-I investigators about protein expression of pX accessory genes in infected individuals. The reason for this is that antibodies to some of those accessory proteins are not easily found in HTLV-I-infected individuals. This scepticism must now be put into perspective in view of the finding of cytotoxic T-lymphocytes (CTL) in HTLV-Iinfected individuals (HAM/TSP and ATL patients and asymptomatic carriers) against peptides contained within pX ORF I and II. In addition, uncultured purified CD8 + T-lymphocytes from HTLV-I-infected individuals contain interferon ␥-producing effector cells to different p27 I /Rof and p30 II /Tof peptides, strongly supporting that full-length Rof and Tof are chronically produced in a majority of HTLV-I carriers. Moreover, the finding of CTL against Rof and Tof and thus the production of Rof and Tof seems to be a common feature of HTLV-I infection and does not depend on the clinical status of infected individuals.
Accessory genes in bovine leukemia virus (BLV)
BLV has been and still is a model that inspires research in the field of HTLV. But now, there is cross-fertilization of ideas from the field of both viruses. The X region of BLV contains two ORF for putative accessory proteins, R3 and G4. Although the proteins have not been detected in infected animals (up to now that is), those ORF are required for efficient viral replication in vivo. G4, but not R3, is necessary for immortalization of primary cells in vitro and for full malignant transformation in cooperation with the Ha-ras oncogene. Viruses deleted in R3 and/or G4 are still infectious, but propagate at a far lower rate than viruses without those mutations. Using a yeast two-hybrid system, it was found that G4 interacts with farnesyl pyrophosphate synthetase (FPPS), a protein that plays a role in the mevalonate/squalene pathway and in the prenylation of Ras oncogene product (G4 protein itself does not seem to be prenylated).
Structural biology
A NMR-derived structure of the HTLV-I capsid protein was presented at the meeting. It consists of amino-and carboxyterminus domains, connected by a flexible linker. The structure of the two former domains is similar to that found in the capsid protein of HIV-1 and equine infectious anemia virus (EIAV), but with one important difference. The conserved cysteine residues in the carboxy-terminus domain of HTLV-I are 'buried away', while those in HIV-1 and EIAV project 'to the outside'. As a result, HIV-1 and EIAV capsid protein form disulfide bonds and are thus the subject of dimerization, while HTLV-I capsid remains monomeric in solution.
